KBC Group
PTGX icon

KBC Group’s Protagonist Therapeutics PTGX Stock Holding History

KBC Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$166K Hold
1,574
– – ﹤0.01% 1045
2025
Q4 		$137K Hold
1,574
– – ﹤0.01% 1101
2025
Q3 		$105K Hold
1,574
– – ﹤0.01% 1228
2025
Q2 		$87K Sell
1,574
-519
-25% -$24.9K ﹤0.01% 1289
2025
Q1 		$101K Hold
2,093
– – ﹤0.01% 1475
2024
Q4 		$81K Buy
2,093
+737
+54% +$32.1K ﹤0.01% 1676
2024
Q3 		$61K Hold
1,356
– – ﹤0.01% 1624
2024
Q2 		$47K Buy
1,356
+154
+13% +$4.51K ﹤0.01% 1655
2024
Q1 		$35K Buy
+1,202
New +$32.7K ﹤0.01% 1720

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

KBC Group's PTGX Position: Q1 2026 in Review

KBC Group held its Protagonist Therapeutics (PTGX) position steady in Q1 2026 at 1,574 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #1045.

KBC Group first reported a position in PTGX in Q1 2024 and has held it in 9 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • KBC Group held 1,574 shares of Protagonist Therapeutics worth $166K as of Q1 2026.
  • KBC Group left its Protagonist Therapeutics share count unchanged in Q1 2026.
  • Protagonist Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1045 holding.
  • KBC Group first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.